Determination of lipophilicity for antitumor acridinone derivatives supported by gradient high-performance liquid chromatography method

• Authors: Marcin Koba , Mariusz Belka , Tomasz Ciesielski , Tomasz Bączek
• Languages of publication: EN

Abstracts

EN

The lipophilicity values of selected acridinone (imidazoacridinone and triazoloacridinone) derivatives were measured by gradient reversed-phase high-performance liquid chromatography (RP-HPLC) using a C18 stationary phase with a water/acetonitrile mixture as a mobile phase. The retention times obtained served as input data and appropriate log kw values (i.e., the retention factor log kw extrapolated to 0% organic modifier) as an alternative to log P were calculated using the DryLab program. The relationships between the lipophilicity (log kw) and the chemical structure of the studied compounds, as well as correlation between experimentally determined lipophilicities (log kw) and log P data calculated using some commonly available software, are discussed.

Keywords

EN

Lipophilicity; Gradient reversed-phase high-performance liquid chromatography (RP-HPLC)

• Publisher: De Gruyter Open
• Journal: Open Chemistry
• Year: 2012
• Volume: 10
• Issue: 1
• Pages: 216-223

Dates

published

1 - 2 - 2012

online

24 - 11 - 2011

Contributors

author

Marcin Koba

• Collegium Medicum of Nicolaus Copernicus University

author

Mariusz Belka

• Medical University of Gdańsk

author

Tomasz Ciesielski

• Norwegian University of Science and Technology

author

Tomasz Bączek

References

• [1] [1]M. Koba, T. Baczek, Curr. Pharm. Anal. 7, 286 (2011)
• [2] [2]N. Isambert, M. Campone, E. Bourbouloux, M. Drouin, A. Major, W. Yin, P. Loadman, R. Capizzi, C. Grieshaber, P. Fumoleau, Eur. J. Cancer 46, 729 (2010) http://dx.doi.org/10.1016/j.ejca.2009.12.005[Crossref]
• [3] [3]M. Sabisz, J. Wesierska-Gadek, A. Skladanowski, Biochem. Pharmacol. 79, 1387 (2010) http://dx.doi.org/10.1016/j.bcp.2009.12.023[Crossref]
• [4] [4]A. Leo, C. Hansch, D. Elkins, Chem. Rev. 71, 525 (1971) http://dx.doi.org/10.1021/cr60274a001[Crossref]
• [5] [5]R. Kaliszan, Trends Anal. Chem. 18, 400 (1999) http://dx.doi.org/10.1016/S0165-9936(99)00120-X[Crossref]
• [6] [6]R. Kaliszan, Structure and Retention in Chromatography. A Chemometric Approach, (Harwood Academic, Amsterdam, 1997)
• [7] [7]M.H. Abraham, H.S. Chadha, R.A.E. Leitao, R.C. Mitchell, W.J. Lambert, R. Kaliszan, A. Nasal, J. Chromatogr. A 766, 35 (1997) http://dx.doi.org/10.1016/S0021-9673(96)00977-6[Crossref]
• [8] [8]L.R. Snyder, J.W. Dolan, Adv. Chromatogr. 38, 115 (1998)
• [9] [9]M.A. Quarry, R.L. Grob, L.R. Snyder, Anal. Chem. 58, 907 (1986) http://dx.doi.org/10.1021/ac00295a056[Crossref]
• [10] [10]I. Moriguchi, S. Hirono, Q. Liu, I. Nakagome, Y. Matsushita, Chem. Pharm. Bull. 40, 127 (1992) http://dx.doi.org/10.1248/cpb.40.127[Crossref]
• [11] [11]V.N. Viswanadhan, A.K. Ghose, G.R. Revankar, R.K. Robins, J. Chem. Inf. Comput. Sci. 29, 163 (1989) http://dx.doi.org/10.1021/ci00063a006[Crossref]
• [12] [12]I.V. Tetko, Drug Discov. Today 10, 1497 (2005) http://dx.doi.org/10.1016/S1359-6446(05)03584-1[Crossref]
• [13] [13]A.R. Leach, V.J. Gillet, An Introduction to Chemoinformatics. (Kluwer Academic Publishers, Dordrecht, 2003)
• [14] [14]A.J. Leo, D. Hoekman, Persp. Drug Discov. Design 18, 19 (2000) http://dx.doi.org/10.1023/A:1008739110753[Crossref]
• [15] [15]J.M. Morris, P.P. Bruneau, Prediction of Physicochemical Properties. In: H.J. Bohn, G. Schneider, (Eds.), Virtual Screening for Bioactive Molecules (Wiley-VCH, Weinheim, 2000) 22
• [16] [16]S. Gocan, G. Cimpan, J. Comer, Adv. Chromatogr. 44, 79 (2006)
• [17] [17]A. Nasal, D. Siluk, R. Kaliszan, Curr. Med. Chem. 10, 381 (2003)
• [18] [18]K. Valko, J. Chromatogr. A 1037, 299 (2004) http://dx.doi.org/10.1016/j.chroma.2003.10.084[Crossref]
• [19] [19]R. Kaliszan, P. Haber, T. Bączek, D. Siluk, K. Valko, J. Chromatogr. A 965, 117 (2002) http://dx.doi.org/10.1016/S0021-9673(02)00114-0[Crossref]
• [20] [20]T. Baczek, R. Kaliszan, J. Chromatogr. A 987, 29 (2003) http://dx.doi.org/10.1016/S0021-9673(02)01701-6[Crossref]
• [21] [21]M. Koba, T. Baczek, Med. Chem. Res. 20, 1385 (2011) http://dx.doi.org/10.1007/s00044-010-9487-y[Crossref]
• [22] [22]M. Koba, T. Baczek Lett. Drug Design Discov. 7, 494 (2010) http://dx.doi.org/10.2174/157018010791526278[Crossref]
• [23] [23]Z. Mazerska, E. Augustin, J. Dziegielewski, W.M. Cholody, J. Konopa, Anticancer Drug Des. 11, 73 (1996)
• [24] [24]A. Skladanowski, S.Y. Plisov, J. Konopa, A.K. Larsen, Mol. Pharmacol. 49, 772 (1996) [PubMed]

Identifiers

DOI

10.2478/s11532-011-0131-6